Substance / Medication

Clobazam

Overview

Active Ingredient
clobazam
RxNorm CUI
21241

Indications

Clobazam tablets are indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older.

Labeler: Amneal Pharmaceuticals NY LLCUpdated: 2026-02-16T00:00:00.000ZFull label on DailyMed

Boxed Warning

FDA Black Box Warning

Warnings and Precautions 5.1 Drug Interactions 7.1 [see(),()]. Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. L

Contraindications

When this intervention should not be used

5.6 5.7 [see Warnings and Precautions (,)] Clobazam tablets are contraindicated in patients with a history of hypersensitivity to the drug or its ingredients. Hypersensitivity reactions have included serious dermatological reactions.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Safety profile of clobazam in the real world: an analysis of FAERS database and systematic review of case reports.
An Pengjiao, Liu Xin, Zhang Bo · Expert Opin Drug Saf · 2024
PMID: 37070461Meta-Analysis
Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials.
Gunning Boudewijn, Mazurkiewicz-Bełdzińska Maria, Chin Richard F M et al. · Acta Neurol Scand · 2021
PMID: 32969022Meta-AnalysisFull text (PMC)
Cannabidiol efficacy and clobazam status: A systematic review and meta-analysis.
Lattanzi Simona, Trinka Eugen, Striano Pasquale et al. · Epilepsia · 2020
PMID: 32452532Meta-Analysis
Cannabidiol efficacy independent of clobazam: Meta-analysis of four randomized controlled trials.
Devinsky Orrin, Thiele Elizabeth A, Wright Stephen et al. · Acta Neurol Scand · 2020
PMID: 32592183Meta-AnalysisFull text (PMC)
Clobazam monotherapy for focal or generalized seizures.
Arya Ravindra, Giridharan Nisha, Anand Vidhu et al. · Cochrane Database Syst Rev · 2018
PMID: 29995989Meta-AnalysisFull text (PMC)
Clobazam monotherapy for partial-onset or generalized-onset seizures.
Arya Ravindra, Anand Vidhu, Garg Sushil K et al. · Cochrane Database Syst Rev · 2014
PMID: 25280512Meta-Analysis
Clobazam as an add-on in the management of refractory epilepsy.
Michael B, Marson A G · Cochrane Database Syst Rev · 2008
PMID: 18425899Meta-Analysis
Sleep, BDNF, and beyond: A comparative study of zolpidem and clobazam in insomnia treatment.
Kumar Vishal, Halder Sumita, Srivastava Shruti et al. · Sleep Med · 2026
PMID: 41197179RCT
Clinical Impact of Co-medication of Levetiracetam and Clobazam with Proton Pump Inhibitors: A Drug Interaction Study.
Pasupuleti Bhuvanachandra, Gone Vamshikrishna, Baddam Ravali et al. · Curr Drug Metab · 2020
PMID: 32067615RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Clobazam (substance)
SNOMED CT
387572002
UMLS CUI
C0055891
RxNorm CUI
21241
Labeler
Amneal Pharmaceuticals NY LLC

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.